Israel
Intratech Medical is a pioneering company dedicated to revolutionizing cardiac care with its innovative product, the Booster™ spiral balloon. This groundbreaking technology aims to semi-occlude the coronary sinus, significantly enhancing the efficacy of coronary intervention for patients experiencing acute myocardial infarction (AMI).
With approximately 16 million people worldwide suffering from heart attacks annually, the impact of AMI-related heart failure on patient health and quality of life cannot be overstated, affecting up to 30% of AMI patients. Intratech's Booster™ balloon, with its unique spiral design, plays a pivotal role post-revascularization of the blocked artery. Once placed in the coronary sinus vein, it elevates vascular pressure, thereby improving blood perfusion into the affected myocardium, ultimately bolstering the patient's cardiac function.
Intratech has demonstrated highly promising pre-clinical results and marked a significant milestone by initiating its First-In-Human clinical trial in 2021. Moreover, the company has successfully secured substantial investment from a key strategic corporation in the interventional cardiology sphere, underscoring the industry's acknowledgment of its potential. Additionally, boasting a comprehensive patent portfolio with global grants, Intratech is positioned at the forefront of innovation in cardiac intervention.
Founded in Israel, Intratech Medical stands as a beacon of hope for AMI patients and signifies a transformative leap in cardiac care, holding promise for vast improvements in patient outcomes and quality of life.
